Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies

Abstract excerpt

Despite the introduction of many novel therapies into the clinic to target hematological malignancies, glucocorticoids (GCs) still remain one of the cornerstone drugs in first-line treatment of lymphoid tumors. However, a significant portion of the patients display acquired GC therapy resistance. This review will describe the different molecular mechanisms that contribute to GC resistance in lymphoid tumors....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Cell Function and Interaction
• Share to Immunotherapy and Immune Responses
• Share to Lymphoma Diagnosis and Treatment